

Supplementary Fig. S3 Full-text RCTs by (a) NICE STA assessment of full-text RCTs in two studies and (b) Jadad score of full-text RCTs in two studies.<sup>12</sup>



## a. NICE STA





## b. Jadad score

NICE National Institute for Health and Care Excellence, RCT randomized controlled trial, STA single technology appraisal.

## References

1. Wisman LAB, et al. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Clin Drug Investig. 2014;34:887-94. 2. Yin D, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol. 2014;78:1281-90.